摘要
目的探讨三阴性乳腺癌中肿瘤区域免疫细胞中程序性死亡配体-1(PD-L1)表达的与各临床病理参数相关性。方法对123例三阴性乳腺癌采用免疫组化法检测PD-L1的表达,整理并分析数据。结果123例乳腺癌组织中,PDL1阳性率为55.3%(68/123)。PD-L1的表达与Ki-67增殖指数的表达、P53表达、组织学分级、肿瘤大小中的差异具有统计学意义(P<0.05)。进一步回归分析发现,P53突变型表达是PD-L1高表达的危险因素。而PD-L1表达与患者的患病年龄、淋巴管瘤栓、腋窝淋巴结转移比较,差异无统计学意义(P>0.05)。结论PD-L1在TNBC中高表达,可以作为TNBC免疫治疗的靶标;TNBC中肿瘤体积大,高组织学分级,Ki-67高增殖指数,P53突变型表达均是PD-L1高表达的影响因素,可能可以作为肿瘤治疗及预测预后的新靶点、新指标。
Objective To investigate the expression and clinical significance of programmed death-ligand 1(PD-L1)in triple-negative breast cancer.Methods The tissues of 123 patients with triple-negative breast cancer were collected.Immuno histochemistry was used to detect the expression of PD-L1.The data wascollated and analyzed.Results The positive rate of PD-L1 was 55.3%(68/123)in 123 breast cancer tissues.The expression of PD-L1 was significantly different from Ki-67 proliferation index,P53 Mutant-type expression,histological gradeand tumor diameter(P<0.05).Further regression analysis showed thatmutant-type expression of P53 was a risk factor for high PD-L1 expression.The expression of PD-L1 had no significant difference with the age of disease,intravascular thrombosis andaxillary lymph node metastasis(P>0.05).Conclusion The high expression of PD-L1 in TNBC can be used as a target for immunotherapy of TNBC.Large tumor diameter,high histological grade,high Ki-67 proliferation index and highmutant-typeexpression of P53 in TNBC are all factors affecting the expression of PD-L1,which may be a new target and indicator for tumor therapy and prognosis prediction.
作者
马进
王春
MA Jin;WANG Chun(Deparment of pathology,People's Hosiptal of Xinjiang Uygur Autonomous Region,Urumqi,830001,China)
出处
《新疆医学》
2023年第5期548-552,共5页
Xinjiang Medical Journal
